A 28-year-old farmer from rural Maharashtra presents with multiple erythematous, scaly patches on his trunk and limbs for 3 weeks. KOH mount shows branching septate hyphae. Regarding the diagnosis and management of tinea corporis, all of the following are correct EXCEPT:
A. Dermatophyte infections in immunocompetent individuals typically require lifelong antifungal prophylaxis to prevent recurrence
B. Topical azoles (miconazole, clotrimazole) applied twice daily for 2–4 weeks is first-line therapy for localized tinea corporis
C. Predisposing factors such as poor hygiene, warm climate, and occlusive clothing should be addressed to reduce recurrence
D. Systemic antifungal therapy with terbinafine or griseofulvin is indicated for extensive involvement (>10% body surface area) or failure of topical therapy
Explanation
Management of Tinea Corporis
Key Point
Dermatophyte infections in immunocompetent individuals do NOT require lifelong prophylaxis. They respond well to finite courses of topical or systemic antifungals with appropriate lifestyle modifications.
Correct Management Principles
First-line therapy for localized disease:
Topical azoles (miconazole, clotrimazole, ketoconazole) or allylamines (terbinafine cream)
Apply twice daily for 2–4 weeks
Continue for 1–2 weeks after clinical resolution to prevent relapse
Indications for systemic therapy:
Extensive involvement (>10% BSA)
Failure of topical therapy after 4 weeks
Involvement of hair-bearing areas (tinea barbae)
Immunocompromised host
Systemic agents:
Table
Agent
Dose
Duration
Notes
Terbinafine
250 mg daily
2–4 weeks
Faster action, preferred
Griseofulvin
500 mg–1 g daily
4–6 weeks
Older agent, longer duration
Itraconazole
200 mg daily
2–4 weeks
Pulse therapy option
High-YieldNEET PG
Recurrence rates in immunocompetent individuals are ~10–20% even after successful treatment — due to reinfection from environment or fomites, NOT treatment failure. Prophylaxis is NOT indicated.
Why Option 2 Is Wrong
Clinical Pearl
Lifelong prophylaxis is:
NOT indicated in immunocompetent individuals
Reserved for severely immunocompromised patients (CD4 <50 cells/μL in HIV/AIDS) or those with recurrent, severe infections
Impractical and unnecessary in the general population
Topical for localized, Reduced area, Extensive → Antifungal systemic, Treatment duration 2–4 weeks, Recurrence prevention via hygiene (not prophylaxis)
Warning
Do not confuse tinea corporis (which rarely recurs if treated adequately) with onychomycosis (which has high recurrence and may warrant prophylaxis in select cases).
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
